Cabaletta Bio, Inc. announced that it has entered into certain work orders relating to Good Manufacturing Practice manufacturing under its existing master services agreement with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization. As part of the agreement, WuXi ATU will serve as a cell processing manufacturing partner for the planned global clinical development of CABA-201 in multiple indications, including potential late-stage clinical trials and commercial readiness activities for CABA-201, in addition to WuXi ATU's current engagement for the MuSK-CAART Phase 1 clinical trial. WuXi ATU will convert the Company's current non-dedicated suite to a dedicated suite for GMP manufacturing for the Company's CABA-201 and MuSK-CAART programs (the Dedicated Suite") for an initial term of eighteen months with two eighteen month extensions at the Company's sole option on six (6) months notice prior to the end of the term.

In addition, the Company agreed to certain monthly minimum runs. In lieu of the existing $1.5 million termination fee under the terms of the WuXi Agreement, the Company would incur a $1.08 million termination fee if it terminates both the CABA-201 and Mu SK-CAART Work Orders for any reason. The Company may terminate for convenience with six months prior written notice, however, the Company may not terminate the Dedicated Suite without termination both MuSK-CAART and CABA-201 GMP run work orders.

In lieu of the existing eight month termination right for convenience under the WuXi Agreement, WuXi ATU may not terminate prior to fifty-four months from the Effective Date.